AGN 194204 clinical trials
Also written NRX194204 and IRX4204.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses AGN 194204 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2008 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Io Therapeutics (4) · University of Southern California (1) · NuRx Pharmaceuticals, Inc. (1)
Studies
Open first, then newest update. How each study uses AGN 194204 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque PsoriasisSuspendedPhase 2Io TherapeuticsNCT06723171Written as IRX4204
- Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCTerminatedPhase 1Io TherapeuticsNCT02991651Written as IRX4204
- Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate CancerCompletedPhase 2Io TherapeuticsNCT01540071Written as NRX 194204
- Study of IRX4204 for Treatment of Early Parkinson's DiseaseCompletedPhase 1Io TherapeuticsNCT02438215Written as IRX4204
- Oral NRX 194204 in Patients With Refractory MalignanciesTerminatedPhase 1University of Southern CaliforniaNCT00630760Written as NRX 194204
- Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 2NuRx Pharmaceuticals, Inc.NCT00964132Written as NRX194204